12:00 AM
Oct 12, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZT-034: Phase I started

Zelos began a single-blind, crossover, U.S. Phase I trial to evaluate single doses of 3 subcutaneous formulations of ZT-034...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >